UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Safe use of perampanel in a carrier of variegate porphyria

Balestrini, S; Hart, Y; Thunell, S; Sisodiya, SM; (2016) Safe use of perampanel in a carrier of variegate porphyria. Practical Neurology 10.1136/practneurol-2015-001305. Green open access

[thumbnail of Balestrini_Practical Neurology final ms.pdf]
Preview
Text
Balestrini_Practical Neurology final ms.pdf

Download (217kB) | Preview

Abstract

Objectives. Treatment of chronic epilepsy in acute porphyrias may be difficult because many antiepileptic drugs can cause activation of clinically-latent conditions. Methods. A 44 year-old lady with drug-resistant chronic epilepsy and a previous genetic diagnosis of variegate porphyria was referred to our epilepsy centre. We started her on perampanel, a structurally novel selective non-competitive AMPA receptor antagonist recently approved for the treatment of partial and secondarily generalized seizures in humans. There are no previous reports about the outcome of exposure to perampanel of carriers of acute porphyria. Results. Perampanel was assessed in silico to be probably not porphyrogenic. Administration of the drug up to 4 mg/day did not lead to elevation of urinary porphobilinogen excretion, nor to any symptoms of acute porphyria after more than 23 months of treatment. Conclusions. Perampanel up to 4 mg/day was tolerated in long-term therapy in this carrier of protoporphyrinogen oxidase deficiency. However, since perampanel is a weak inducer of cytochrome P450 enzymes, vigilance should be maintained for clinical and biochemical signs of activation of acute porphyria when used in a carrier of acute porphyria.

Type: Article
Title: Safe use of perampanel in a carrier of variegate porphyria
Open access status: An open access version is available from UCL Discovery
DOI: 10.1136/practneurol-2015-001305
Publisher version: http://dx.doi.org/10.1136/practneurol-2015-001305
Language: English
Additional information: Copyright © 2016 by the BMJ Publishing Group Ltd. All rights reserved.
Keywords: Epilepsy, Metabolic Disease, Neuropharmacology, Porphyria
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Experimental Epilepsy
URI: https://discovery.ucl.ac.uk/id/eprint/1472947
Downloads since deposit
199Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item